Triple-negative Breast Cancer (TNBC) and Its Luminal Androgen Receptor (LAR) Subtype: A Clinicopathologic Review of Cases in a University Hospital in Northwestern Nigeria

Liman, AA; Kabir, Balarabe; Abubakar, Murtala; Sudi, Abdullahi; Ahmed, SA; Shehu, SM

doi:10.4103/njcp.njcp_437_20

Cited by 3 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significant number of metaplastic carcinoma also corroborates observations made in an earlier Nigerian study by Titloye et al [10]. Invasive carcinoma (NST) constituted the predominant histologic type in all the aforementioned studies [13,24,25,33]. In comparison to Ricciardi et al [25], who found a relatively high proportion of lobular carcinoma (15.5%) and medullary carcinoma (6.6%), our study recorded only one lobular carcinoma (1.6%) and no medullary carcinoma.…”

Section: Discussionsupporting

confidence: 91%

“…The mean age for index study is 49.3years and the mean for Zaria TNBC study population is 42.89 ± 11.88 years which falls under 50 years of age and is similar to median ages of under 50 years reported by Ghanaian (45 years), Egyptian (35.6 years) and Nottingham (49.9 years) study cohorts, respectively [5,13,33,35]. However, the median ages for Yale based study in the USA (65 years), an Italian cohort (58.8 years) and mean age for Iranian population (50.94 years) were all over 50 years [24,25,29].…”

Section: Discussionsupporting

confidence: 73%

“…Other histologic types reported in the current study are invasive metaplastic carcinoma (21.4%), invasive mucinous carcinoma and invasive lobular carcinoma which accounted for 1.6% each. Invasive carcinoma NST (95.5%) accounted for the majority of the histologic phenotype in TNBC while medullary carcinoma, mucinous carcinoma, signet ring cell and papillary carcinoma (4.5%) were one case each in the Zaria study [13]. In the study by Safarpour et al [24], the predominant histologic types were poorly differentiated carcinoma, NST and the classic apocrine carcinoma, which accounted for 10 of 18 (55%) TNBC cases studied.…”

Section: Discussionmentioning

confidence: 93%

“…Previous studies have reported higher proportion of TNBC in people of African descent, including African Americans [4][5][6][7]. In Nigeria, the frequency of TNBC ranges between 13.48% and 52.6% while in Ghana, TNBC constituted 61% of the 147 cases of invasive breast cancer cases studied by Proctor et al [5,[11][12][13][14][15][16]. In Yale USA, Safarpour et al [24] reported 12.5% TNBC out of 400 cases of invasive breast cancer investigated.…”

Section: Discussionmentioning

confidence: 99%

“…Another hospital-based study, at the Jos University Teaching Hospital in North-Central Nigeria, demonstrated a prevalence of 41.3% (26 cases) out of the 63 cases [12]. Liman et al [13] and Usman et al [14] reported 13.48%(89 of 660) and 46.6% (55 of 118) TNBC cases in North-Western Nigeria, respectively. In North-Eastern Nigeria, Minoza et al [15] reported a higher percentage of 52.6% (20 of 38) TNBC cases while Ukah et al [16] in South-Eastern Nigeria reported 46.5% (40 of 86) TNBC cases in their study population, respectively.…”

Section: Introductionmentioning

confidence: 95%

See 4 more Smart Citations

Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria

Haruna¹,

Daramola²,

Awolola³

et al. 2022

ecancer

View full text Add to dashboard Cite

Introduction: Androgen receptor (AR) is one of the predominant nuclear hormone receptors in invasive breast cancer and can be explored as a biomarker of response for targeted anti-androgen therapy, especially in the setting of triple negative breast cancer (TNBC). Luminal AR is a distinct subtype amongst TNBC cases following gene expression studies. TNBC is higher in Africans (23%-82%) and African-Americans (29.8%) compared to Caucasian (10%-15%) breast cancer patients; however, there is a paucity of data on AR expression in this population.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

See 3 more Smart Citations

Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria

Haruna¹,

Daramola²,

Awolola³

et al. 2022

ecancer

View full text Add to dashboard Cite

show abstract

Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review

Natarajan

Raghavendran

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Breast cancer is the most common malignancy and the second most common cause of cancer-related mortality in women. Triple-negative breast cancers do not express estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2 and have a higher recurrence rate, greater metastatic potential, and lower overall survival rate than those of other breast cancers. Treatment of triple-negative breast cancer is challenging; molecular-targeted therapies are largely ineffective and there is no standard treatment. In this review, we evaluate current attempts to classify triple-negative breast cancers based on their molecular features. We also describe promising treatment methods with different advantages and discuss genetic biomarkers and other prediction tools. Accurate molecular classification of triple-negative breast cancers is critical for patient risk categorization, treatment decisions, and surveillance. This review offers new ideas for more effective treatment of triple-negative breast cancer and identifies novel targets for drug development.

show abstract

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer

Khadela

Chavda

Soni

et al. 2022

Cancers

View full text Add to dashboard Cite

Triple-negative tumors are progressively delineating their existence over the extended spectrum of breast cancers, marked by intricate molecular heterogeneity, a low overall survival rate, and an unexplored therapeutic approach. Although the basal subtype transcends the group and contributes approximately 80% to triple-negative breast cancer (TNBC) cases, the exceptionally appearing mesenchymal and luminal androgen receptor (LAR) subtypes portray an unfathomable clinical course. LAR with a distinct generic profile frequently metastasizes to regional lymph nodes and bones. This subtype is minimally affected by chemotherapy and shows the lowest pathologic complete response. The androgen receptor is the only sex steroid receptor that plays a cardinal role in the progression of breast cancers and is typically overexpressed in LAR. The partial AR antagonist bicalutamide and the next-generation AR inhibitor enzalutamide are being assessed in standard protocols for the mitigation of TNBC. There arises an inevitable need to probe into the strategies that could neutralize these androgen receptors and alleviate the trajectory of concerning cancer. This paper thus focuses on reviewing literature that provides insights into the anti-androgenic elements against LAR typical TNBC that could pave the way for clinical advancements in this dynamic sphere of oncology.

show abstract

Triple-negative Breast Cancer (TNBC) and Its Luminal Androgen Receptor (LAR) Subtype: A Clinicopathologic Review of Cases in a University Hospital in Northwestern Nigeria

Cited by 3 publications

References 31 publications

Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria

Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria

Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer

Contact Info

Product

Resources

About